NasdaqGM:STIMMedical Equipment
Neuronetics (STIM) Is Down 9.0% After Turning Cash-Flow Positive On NeuroStar Demand Has The Bull Case Changed?
In the past quarter, Neuronetics reported preliminary fourth-quarter 2025 revenue of US$41.8 million, driven by demand for its NeuroStar systems and clinic operations, and generated US$0.9 million in positive operating cash flow.
This combination of strong top-line growth and the shift to positive operating cash flow highlights progress in scaling its NeuroStar-focused business while managing liquidity pressures.
Next, we’ll explore how the move to positive operating cash flow may influence...